Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
Recent evolutionary studies reveal that microorganisms including yeasts and fungi are more closely related to mammals than was previously appreciated. Possibly as a consequence, many natural-product toxins that have antimicrobial activity are also toxic to mammalian cells. While this makes it difficult to discover antifungal agents without toxic side effects, it also has enabled detailed studies of drug action in simple genetic model systems. We review here studies on the antifungal actions of antineoplasmic agents. Topics covered include the mechanisms of action of inhibitors of topoisomerases I and II; the immunosuppressants rapamycin, cyclosporin A, and FK506; the phosphatidylinositol 3-kinase inhibitor wortmannin; the angiogenesis inhibitors fumagillin and ovalicin; the HSP90 inhibitor geldanamycin; and agents that inhibit sphingolipid metabolism. In general, these natural products inhibit target proteins conserved from microorganisms to humans. These studies highlight the potential of microorganisms as screening tools to elucidate the mechanisms of action of novel pharmacological agents with unique effects against specific mammalian cell types, including neoplastic cells. In addition, this analysis suggests that antineoplastic agents and derivatives might find novel indications in the treatment of fungal infections, for which few agents are presently available, toxicity remains a serious concern, and drug resistance is emerging.
Cardenas
M E
ME
Department of Genetics, Duke University Medical Center, Durham, North Carolina 27710, USA.
Cruz
M C
MC
Del Poeta
M
M
Chung
N
N
Perfect
J R
JR
Heitman
J
J
D000217:Acyltransferases / Q000378:metabolism; D000730:Androstadienes / Q000494:pharmacology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D006801:Humans; D020123:Sirolimus / Q000494:pharmacology; D013107:Sphingolipids / Q000378:metabolism; D016559:Tacrolimus / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors; D000077191:Wortmannin
D000730:Androstadienes; D020533:Angiogenesis Inhibitors; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D013107:Sphingolipids; D059004:Topoisomerase I Inhibitors; D016572:Cyclosporine; D000217:Acyltransferases; C050480:glycylpeptide N-tetradecanoyltransferase; D002945:Cisplatin; D020123:Sirolimus; D016559:Tacrolimus; D000077191:Wortmannin